While many studies associate reduced IGF-1 with increased neurodegeneration, some clinical studies of dementias and stroke see increased IGF-1 levels at the start of pathology, which may be an attempted compensatory mechanism designed to protect the brain (Gubbi et al., 2018; Castilla-Cortazar et al., 2020). The gene discussed is IGF1; the disease is Stroke.